Meeting
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
Authors
Evan Y. Yu
University of Washington, Seattle, WA
Evan Y. Yu , Jose Maria M. Piulats Rodriguez , Gwenaelle Gravis , Brigitte Laguerre , Jose Angel Arranz Arija , Stephane Oudard , Peter C.C. Fong , Michael Paul Kolinsky , Marinela Augustin , Tilman Todenhöfer , Audrey E. Kam , Howard Gurney , Ali Tafreshi , Margitta Retz , William R. Berry , Nataliya Mar , Haiyan Wu , Ping Qiu , Charles Schloss , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02861573
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5544)
DOI
10.1200/JCO.2020.38.15_suppl.5544
Abstract #
5544
Poster Bd #
125
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
First Author: Henry Jacob Conter
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2022 ASCO Genitourinary Cancers Symposium
Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).
First Author: Rana R. McKay